RS66516B1 - 3-sulfopropanska kiselina za lečenje neurodegenerativnih poremećaja - Google Patents

3-sulfopropanska kiselina za lečenje neurodegenerativnih poremećaja

Info

Publication number
RS66516B1
RS66516B1 RS20250164A RSP20250164A RS66516B1 RS 66516 B1 RS66516 B1 RS 66516B1 RS 20250164 A RS20250164 A RS 20250164A RS P20250164 A RSP20250164 A RS P20250164A RS 66516 B1 RS66516 B1 RS 66516B1
Authority
RS
Serbia
Prior art keywords
spa
subject
disease
csf
alzheimer
Prior art date
Application number
RS20250164A
Other languages
English (en)
Serbian (sr)
Inventor
John Hey
Petr Kocis
Martin Tolar
Neil William Flanzraich
Original Assignee
Alzheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzheon Inc filed Critical Alzheon Inc
Publication of RS66516B1 publication Critical patent/RS66516B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
RS20250164A 2018-08-01 2019-07-30 3-sulfopropanska kiselina za lečenje neurodegenerativnih poremećaja RS66516B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862713061P 2018-08-01 2018-08-01
PCT/US2019/044023 WO2020028290A1 (en) 2018-08-01 2019-07-30 Methods for treating neurodegenerative disorders
EP19752795.5A EP3829563B1 (en) 2018-08-01 2019-07-30 3-sulfopropanoic acid for treating neurodegenerative disorders

Publications (1)

Publication Number Publication Date
RS66516B1 true RS66516B1 (sr) 2025-03-31

Family

ID=67614642

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20250164A RS66516B1 (sr) 2018-08-01 2019-07-30 3-sulfopropanska kiselina za lečenje neurodegenerativnih poremećaja

Country Status (27)

Country Link
US (2) US12083082B2 (cg-RX-API-DMAC7.html)
EP (1) EP3829563B1 (cg-RX-API-DMAC7.html)
JP (1) JP7573512B2 (cg-RX-API-DMAC7.html)
KR (1) KR102716959B1 (cg-RX-API-DMAC7.html)
CN (1) CN112867485A (cg-RX-API-DMAC7.html)
AU (1) AU2019315853B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021001739A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021000269A1 (cg-RX-API-DMAC7.html)
DK (1) DK3829563T3 (cg-RX-API-DMAC7.html)
EA (1) EA202190406A1 (cg-RX-API-DMAC7.html)
ES (1) ES3011716T3 (cg-RX-API-DMAC7.html)
FI (1) FI3829563T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250206T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070101T2 (cg-RX-API-DMAC7.html)
IL (1) IL280424B2 (cg-RX-API-DMAC7.html)
LT (1) LT3829563T (cg-RX-API-DMAC7.html)
MX (1) MX2021001287A (cg-RX-API-DMAC7.html)
MY (1) MY206530A (cg-RX-API-DMAC7.html)
PH (1) PH12021550213A1 (cg-RX-API-DMAC7.html)
PL (1) PL3829563T3 (cg-RX-API-DMAC7.html)
PT (1) PT3829563T (cg-RX-API-DMAC7.html)
RS (1) RS66516B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100767XA (cg-RX-API-DMAC7.html)
SI (1) SI3829563T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500080T1 (cg-RX-API-DMAC7.html)
UA (1) UA130011C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020028290A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021001287A (es) * 2018-08-01 2021-07-15 Alzheon Inc Métodos para tratar trastornos neurodegenerativos.
PH12021553196A1 (en) * 2019-06-17 2022-11-07 Alzheon Inc Methods for treating neurodegenerative disorders
AU2022405026A1 (en) * 2021-12-09 2024-06-20 Alzheon, Inc. Alz-801 for use in treating alzheimer's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
SI2089417T1 (sl) * 2006-10-12 2015-04-30 Bhi Limited Partnership Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline
EP2852388A4 (en) 2012-05-23 2016-01-13 Univ Johns Hopkins COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
WO2014121083A1 (en) * 2013-01-31 2014-08-07 President And Fellows Of Harvard College Methods of increasing neuronal connectivity and/or treating a neurodegenerative condition
ES2960625T3 (es) * 2014-03-21 2024-03-05 Alzheon Inc Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+
EP3347002B1 (en) * 2015-09-10 2023-06-07 Alzheon, Inc. Treatment of alzheimer's disease in a particular patient population
MX2021001287A (es) * 2018-08-01 2021-07-15 Alzheon Inc Métodos para tratar trastornos neurodegenerativos.

Also Published As

Publication number Publication date
EP3829563A1 (en) 2021-06-09
US20250213507A1 (en) 2025-07-03
ES3011716T3 (en) 2025-04-08
EA202190406A1 (ru) 2021-10-15
BR112021001739A2 (pt) 2021-04-27
HUE070101T2 (hu) 2025-05-28
AU2019315853A1 (en) 2021-03-18
KR102716959B1 (ko) 2024-10-11
SMT202500080T1 (it) 2025-03-12
US12083082B2 (en) 2024-09-10
LT3829563T (lt) 2025-02-25
CL2021000269A1 (es) 2021-06-18
PL3829563T3 (pl) 2025-04-07
IL280424B2 (en) 2025-01-01
SI3829563T1 (sl) 2025-05-30
MY206530A (en) 2024-12-19
SG11202100767XA (en) 2021-02-25
AU2019315853B2 (en) 2025-05-01
JP2021533128A (ja) 2021-12-02
MX2021001287A (es) 2021-07-15
EP3829563B1 (en) 2024-11-20
UA130011C2 (uk) 2025-10-15
CN112867485A (zh) 2021-05-28
IL280424B1 (en) 2024-09-01
KR20210039415A (ko) 2021-04-09
US20210315847A1 (en) 2021-10-14
PH12021550213A1 (en) 2021-11-03
FI3829563T3 (fi) 2025-02-17
CA3108150A1 (en) 2020-02-06
WO2020028290A1 (en) 2020-02-06
PT3829563T (pt) 2025-02-18
HRP20250206T1 (hr) 2025-04-11
DK3829563T3 (en) 2025-02-24
JP7573512B2 (ja) 2024-10-25
IL280424A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
US20250213507A1 (en) Methods for treating neurodegenerative disorders
US20260034088A1 (en) Sulfopropanoic acid derivatives for treating neurodegenerative disorders
AU2016319107A1 (en) Methods of treating neurodegenerative disorders in a particular patient population
CA3108150C (en) Methods for treating neurodegenerative disorders
HK40056250B (en) 3-sulfopropanoic acid for treating neurodegenerative disorders
HK40056250A (en) 3-sulfopropanoic acid for treating neurodegenerative disorders
EA048644B1 (ru) Способы лечения нейродегенеративных расстройств
HK40105684B (en) Sulfopropanoic acid derivatives for treating neurodegenerative disorders
HK40105684A (en) Sulfopropanoic acid derivatives for treating neurodegenerative disorders
HK40056251B (en) Sulfopropanoic acid derivatives for treating neurodegenerative disorders
HK40056251A (en) Sulfopropanoic acid derivatives for treating neurodegenerative disorders
EA052917B1 (ru) Способы лечения нейродегенеративных расстройств